At what pace is the vyndaqel market growing, and what is its estimated value?
The vyndaqel market size has grown rapidly in recent years. It will grow from $1.62 billion in 2024 to $1.91 billion in 2025 at a compound annual growth rate (CAGR) of 18.1%. The growth in the historic period can be attributed to increasing transthyretin amyloidosis awareness, increasing prevalence of transthyretin-mediated amyloidosis cardiomyopathy, increasing focus on rare diseases, growing government support, rising clinical trials, growing geriatric population.
The vyndaqel market size is expected to see rapid growth in the next few years. It will grow to $3.67 billion in 2029 at a compound annual growth rate (CAGR) of 17.1%. The growth in the forecast period can be attributed to increasing investment in research and developments, growing adoption of precision medicine, increasing physician familiarity, increasing availability of diagnostic tools, growing government initiatives. Major trends in the forecast period include telemedicine facility, strategic collaboration, advancements in genetic testing, digital health tools, personalized medicine.
Get Your Free Sample of The Global Vyndaqel Market Report:
Vyndaqel Market Report 2025
What are the top drivers to the rising demand in the vyndaqel market?
The increasing investment in research and development is expected to propel the growth of the vyndaqel market going forward. Research and development refers to innovating and improving products, services, or processes through systematic investigation and experimentation. The increasing investment in research and development is due to the rising prevalence of neurological disorders, advancements in medical technology, growing awareness and demand for innovative treatments, and substantial government and private sector funding initiatives. Investment in research and development accelerates the development and optimization of therapies and enhances efficacy and accessibility for patients. It drives advancements in vyndaqel, improving its effectiveness, accessibility, and potential for expanded indications. For instance, in July 2024, according to the Department of Health and Social Care, a UK-based government department, the business enterprise sector in the UK conducted pharmaceutical research and development amounting to approximately $11.1 billion in 2922, representing 0.36% of the nation’s gross domestic product. Therefore, the increasing investment in research and development is driving the growth of the vyndaqel market.
Rising Adoption Of Precision Medicine Driving Growth In The Market
The growing adoption of precision medicine is expected to propel the growth of the vyndaqel market going forward. Personalized medicine refers to tailoring medical treatment to individual patients based on their genetic, environmental, and lifestyle factors. The adoption of personalized medicine is growing due to advancements in genomic research, improved treatment efficacy, and the rising prevalence of chronic diseases. The adoption of personalized medicine positively impacts Vyndaqel by enabling more precise diagnosis and targeted treatment for transthyretin amyloidosis (ATTR), ensuring that patients who will benefit most from the drug receive it. This approach enhances treatment efficacy, improves patient outcomes, and supports market growth by increasing the demand for specialized therapies such as Vyndaqel. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the US Food and Drug Administration (FDA) approved 16 novel personalized therapies for patients with rare diseases in 2023, up from six in 2022. Therefore, the growing adoption of precision medicine is driving the growth of the vyndaqel market.
Facility Expansions Driving Growth In The Market
Major companies operating in the vyndaqel market is focusing on facility expansions to produce active pharmaceutical ingredients. Facility expansion refers to the process of increasing the physical infrastructure, production capacity, or operational capabilities of a business to accommodate growth, improve efficiency, or meet rising demand. For instance, in July 2024, Pfizer Inc., a US-based pharmaceutical company manufacturing vyndaqel, opened a $1 billion plant in Singapore’s Tuas Biomedical Park. Pfizer’s new 429,000 sq ft facility in Tuas Biomedical Park will manufacture active pharmaceutical ingredients (APIs) for its cancer, pain, and antibiotic medicines. As an extension of Pfizer’s existing site, which has been operating for 20 years, the plant is set to create 250 highly skilled jobs. The facility is recognized with a Green Mark Gold certification for its environmental sustainability efforts and aligns with Pfizer’s commitment to achieving net-zero emissions by 2040.
How is the vyndaqel market segmented?
The vyndaqel market covered in this report is segmented –
1) By Product Type: Vyndaqel (Tafamidis 20 mg), Vyndamax (Tafamidis 61 mg)
2) By Disease Type: Familial Amyloid Polyneuropathy (FAP), Wild-Type Or Hereditary Transthyretin-Mediated Amyloidosis Cardiomyopathy (ATTR-CM)
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
Subsegments:
1) By Vyndaqel (Tafamidis 20 mg): Oral Tablets, Oral Solution
2) By Vyndamax (Tafamidis 61 mg): Oral Capsules, Oral Suspension
Order your report now for swift delivery
Vyndaqel Market Report 2025
Who are the top competitors in the vyndaqel market?
Major companies operating in the vyndaqel market are Pfizer Inc.
Which regional trends are influencing the vyndaqel market, and which area dominates the industry?
North America was the largest region in the vyndaqel market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the vyndaqel market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Vyndaqel Market Report 2025 Offer?
The vyndaqel market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Vyndaqel refers to tafamidis, a medication used to treat transthyretin amyloid cardiomyopathy (ATTR-CM), a heart condition caused by the buildup of misfolded transthyretin proteins. It stabilizes the transthyretin protein, preventing its misfolding and accumulation in the heart. Vyndaqel is used to reduce cardiovascular-related deaths and hospitalizations in patients with ATTR-CM. It is also prescribed to improve the quality of life for individuals suffering from this progressive and often fatal disease.
Purchase the exclusive report now to unlock valuable market insights:
Vyndaqel Market Report 2025
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: The Business Research Company | LinkedIn
Twitter: The Business Research Company (@tbrc_info) on X
Facebook: The Business Research Company | London
YouTube: The Business Research Company
Blog: In-Depth Insights into the Implantable Loop Recorders Market: Growth, Trends, and Opportunities for 2025-2034 – Latest Global Market Insights
Healthcare Blog: Latest Healthcare Research Reports – By The Business Research Company
Global Market Model: Global Market Intelligence Database
